PURPOSE: In September 2012 an interactive course on the "Interface Management of Pharmacotherapy" was organized by the Stockholm Drug and Therapeutics Committee in cooperation with Department of Clinical Pharmacology at Karolinska Institutet and at Karolinska University Hospital in Stockholm, Sweden, in collaboration with the WHO. The basis for the course was the "Stockholm model" for the rational use of medicines but also contained presentations about successful models in interface management of pharmacotherapy in other European countries. METHODS: The "Stockholm model" consists of 8 components: 1) Independent Drug and Therapeutics Committee with key role for respected drug experts with policy for "interest of conflicts", 2) The "Wise List", recommendations of medicines jointly for primary and hospital care, 3) Communication strategy with continuous medical education, 4) Systematic introduction of new expensive medicines, 5) E-pharmacological support at "point of care", 6) Methods and tools for follow-up of medicines use, 7) Medicines policy strategy and 8) Operative resources. RESULTS: The course highlighted the importance of efficient and targeted communication of drug recommendations building on trust among prescribers and patients for the guidelines to achieve high adherence. Trust is achieved by independent Drug and Therapeutics Committees with a key role for respected experts and a strict policy for "conflicts of interest". Representations of GPs are also crucial for successful implementation, being the link between evidence based medicine and practice. CONCLUSION: The successful models in Scotland and in Stockholm as well as the ongoing work in Catalonia were considered as examples of multifaceted approaches to improve the quality of medicine use across primary and hospital care.
PURPOSE: In September 2012 an interactive course on the "Interface Management of Pharmacotherapy" was organized by the Stockholm Drug and Therapeutics Committee in cooperation with Department of Clinical Pharmacology at Karolinska Institutet and at Karolinska University Hospital in Stockholm, Sweden, in collaboration with the WHO. The basis for the course was the "Stockholm model" for the rational use of medicines but also contained presentations about successful models in interface management of pharmacotherapy in other European countries. METHODS: The "Stockholm model" consists of 8 components: 1) Independent Drug and Therapeutics Committee with key role for respected drug experts with policy for "interest of conflicts", 2) The "Wise List", recommendations of medicines jointly for primary and hospital care, 3) Communication strategy with continuous medical education, 4) Systematic introduction of new expensive medicines, 5) E-pharmacological support at "point of care", 6) Methods and tools for follow-up of medicines use, 7) Medicines policy strategy and 8) Operative resources. RESULTS: The course highlighted the importance of efficient and targeted communication of drug recommendations building on trust among prescribers and patients for the guidelines to achieve high adherence. Trust is achieved by independent Drug and Therapeutics Committees with a key role for respected experts and a strict policy for "conflicts of interest". Representations of GPs are also crucial for successful implementation, being the link between evidence based medicine and practice. CONCLUSION: The successful models in Scotland and in Stockholm as well as the ongoing work in Catalonia were considered as examples of multifaceted approaches to improve the quality of medicine use across primary and hospital care.
Authors: Bengt Sjöborg; Tobias Bäckström; Lars-Bertil Arvidsson; Eva Andersén-Karlsson; L Bengt Blomberg; Birgit Eiermann; Marie Eliasson; Kjell Henriksson; Lennart Jacobsson; Ulf Jacobsson; Margaretha Julander; Per-Olof Kaiser; Carina Landberg; Jonas Larsson; Björn Molin; Lars L Gustafsson Journal: Int J Med Inform Date: 2006-04-19 Impact factor: 4.046
Authors: Ylva Böttiger; Kari Laine; Marine L Andersson; Tuomas Korhonen; Björn Molin; Marie-Louise Ovesjö; Tuire Tirkkonen; Anders Rane; Lars L Gustafsson; Birgit Eiermann Journal: Eur J Clin Pharmacol Date: 2009-02-11 Impact factor: 2.953
Authors: R Fernández Urrusuno; P Pérez Pérez; M C Montero Balosa; C Márquez Calzada; B Pascual de la Pisa Journal: Eur J Clin Pharmacol Date: 2013-12-03 Impact factor: 2.953
Authors: Wenjie Zeng; Alexander E Finlayson; Sushma Shankar; Winnie de Bruyn; Brian Godman Journal: BMC Health Serv Res Date: 2015-01-22 Impact factor: 2.655
Authors: Jaran Eriksen; Lars L Gustafsson; Kristina Ateva; Pia Bastholm-Rahmner; Marie-Louise Ovesjö; Malena Jirlow; Maria Juhasz-Haverinen; Gerd Lärfars; Rickard E Malmström; Björn Wettermark; Eva Andersén-Karlsson Journal: BMJ Open Date: 2017-05-02 Impact factor: 2.692
Authors: Pia Bastholm-Rahmner; Lars L Gustafsson; Kristina Aggefors; Kristina Ateva; Susanne Elfving; Jaran Eriksen; Malena Jirlow; Maria Juhasz-Haverinen; Rickard E Malmström; Mahan Nikpour-Ardaly; Magnus Röjvall; Martina Vallin; Eva Andersén-Karlsson; Marie-Louise Ovesjö Journal: BMC Health Serv Res Date: 2018-03-12 Impact factor: 2.655
Authors: Jaran Eriksen; Marie-Louise Ovesjö; Martina Vallin; Maria Juhasz-Haverinen; Eva Andersén-Karlsson; Kristina Ateva; Lars L Gustafsson; Malena Jirlow; Pia Bastholm-Rahmner Journal: Eur J Clin Pharmacol Date: 2017-10-23 Impact factor: 2.953
Authors: Winnie de Bruijn; Cristina Ibáñez; Pia Frisk; Hanne Bak Pedersen; Ali Alkan; Patricia Vella Bonanno; Ljiljana S Brkičić; Anna Bucsics; Guillaume Dedet; Jaran Eriksen; Joseph O Fadare; Jurij Fürst; Gisselle Gallego; Isabella P Godói; Augusto A Guerra Júnior; Hakkı Gürsöz; Saira Jan; Jan Jones; Roberta Joppi; Saim Kerman; Ott Laius; Newman Madzikwa; Einar Magnússon; Mojca Maticic; Vanda Markovic-Pekovic; Amos Massele; Olayinka Ogunleye; Aisling O'Leary; Jutta Piessnegger; Catherine Sermet; Steven Simoens; Celda Tiroyakgosi; Ilse Truter; Magnus Thyberg; Kristina Tomekova; Magdalena Wladysiuk; Sotiris Vandoros; Elif H Vural; Corinne Zara; Brian Godman Journal: Front Pharmacol Date: 2016-07-22 Impact factor: 5.810